This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Patient Registry Study of Berinert® in Normal Clinical Practice

This study has been completed.
Chiltern International Inc.
Information provided by (Responsible Party):
CSL Behring Identifier:
First received: April 12, 2010
Last updated: June 5, 2014
Last verified: June 2014
The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.

Condition Intervention
Includes: Hereditary Angioedema Biological: Berinert® (C1 Esterase Inhibitor)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Patient Registry for Berinert®, a C1-Esterase Inhibitor

Resource links provided by NLM:

Further study details as provided by CSL Behring:

Primary Outcome Measures:
  • Incidence of thrombotic and thrombo-embolic events [ Time Frame: Within 30 days of treatment with Berinert® ]
  • Occurrence of suspected viral transmission [ Time Frame: Duration of the study, at least 3 years ]
  • Use of concomitant medications and plasma products [ Time Frame: Duration of the study, at least 3 years ]

Enrollment: 318
Study Start Date: April 2010
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients requiring treatment with Berinert®
Biological: Berinert® (C1 Esterase Inhibitor)
Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
Other Names:
  • C1-INH
  • Berinert P
  • CE1145


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
An attempt will be made to prospectively identify patients and enroll them into this registry before treatment is required. In addition, retrospective chart/case review and data collection may be conducted.

Inclusion Criteria:

  • Any patient receiving CSL Behring's C1-esterase inhibitor
  • Written informed consent (may not be required for some retrospective chart review cases)

Exclusion Criteria:

  • Any patient participating in an HAE study using other C1-inhibitors than Berinert®
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01108848

  Show 40 Study Locations
Sponsors and Collaborators
CSL Behring
Chiltern International Inc.
Study Director: Global Clinical Program Director CSL Behring
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: CSL Behring Identifier: NCT01108848     History of Changes
Other Study ID Numbers: CE1145_5002
1500 ( Other Identifier: CSL Behring )
Study First Received: April 12, 2010
Last Updated: June 5, 2014

Keywords provided by CSL Behring:
C1-esterase Inhibitor
Hereditary angioedema
Acute HAE attack

Additional relevant MeSH terms:
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Genetic Diseases, Inborn
Complement C1s
Complement C1 Inhibitor Protein
Complement C1 Inactivator Proteins
Immunologic Factors
Physiological Effects of Drugs
Complement Inactivating Agents
Immunosuppressive Agents processed this record on July 27, 2017